Skip to main content

Table 3 Cox regression model* for the effect of continuous variables, including features of the metabolic syndrome as defined by ATPIII, on the risk of total CVD events in patients assigned to placebo in the FIELD study

From: Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

Variable† Hazard ratio (95% CI) P
Predictive variable   
Female (at 62 years) 0.70 (0.55-0.88) 0.003
Age (per 10 years): male 1.21 (1.06-1.39) < 0.001
Age (per 10 years): female 1.74 (1.38-2.19)  
Prior CVD (at 140 mmHg SBP, 6.85% HbA1c) 2.14 (1.81-2.53) < 0.001
Hemoglobin A1c (per 1%): no prior CVD 1.18 (1.10-1.26) < 0.001
Hemoglobin A1c (per 1%): prior CVD 1.03 (0.95-1.13)  
Creatinine (per 20 μmol/L) 1.21 (1.09-1.35) < 0.001
Metabolic syndrome variable‡   
Waist -hip ratio (per 0.1) 1.03 (0.91-1.17) 0.60
Systolic BP (per 10 mmHg): no prior CVD 1.16 (1.09-1.24) < 0.001
Systolic BP (per 10 mmHg): prior CVD 1.01 (0.94-1.09)  
Triglycerides (per 0.5 mmol/L) 1.03 (0.99-1.07) 0.19
HDL-c (per 0.1 mmol/L) 0.94 (0.90-0.97) < 0.001
Urine albumin-creatinine ratio (per doubling) 1.06 (1.02 - 1.10) 0.002
  1. * Cox proportional-hazards assumptions were met.
  2. † All variables were centered at medians. Standard deviations for distributions of the continuous variables were: age, 6.9 years; HbA1c, 1.35%; creatinine, 15.8 μmol/L; waist, 13 cm; systolic BP, 15 mmHg; triglycerides, 0.88 mmol/L; HDL-c, 0.26 mmol/L.
  3. ‡ Corrected for age, sex, prior CVD, baseline HbA1c and creatinine.
  4. ATPIII, Adult Treatment Panel III; CVD, cardiovascular disease; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; BP, blood pressure; HDL-c, high-density lipoprotein cholesterol